CONFERENCE PROCEEDING
Development and evaluation of 3-hydroxyquinoline-4-carboxylic acid derivatives for ASGPR-targeted drug delivery
,
 
 
 
More details
Hide details
1
Department of Chemistry, M. V. Lomonosov Moscow State University, Moscow, Russia
 
2
D. Mendeleev University of Chemical Technology of Russia, Moscow, Russia
 
3
National University of Science and Technology MISIS, Moscow, Russia
 
4
Research Institute “Nanotechnology and Nanomaterials”, G.R. Derzhavin Tambov State University, Tambov, Russia
 
 
Publication date: 2021-09-27
 
 
Public Health Toxicol 2021;1(Supplement 1):A25
 
ABSTRACT
The asialoglycoprotein receptor (ASGPR) is a C-type (Ca2+-dependent) lectin which is highly expressed on the surface of hepatocytes. The primary physiological role of ASGPR is considered to be binding, internalization, and subsequent clearance from the circulation of galactose- and N-acetylgalactosamine-terminated glycoproteins. The location and the function make the receptor an ideal target for delivery of therapeutic agents to liver cells.
Discovery of new ligands is an important goal in drug delivery. Quinoline derivatives has shown to be potent inhibitors of another C-type lectin (P-selectin)1,2,3, marching to the clinical studies for the treatment of athero-thrombotic vascular events. Similar structures were obtained in the previously reported4 rational in silico screening for ASGPR ligands, albeit the measured affinity was relatively low. In this work we try to optimize the affinity of quinoline derivative structure. After in silico screening sixteen 3-hydroxyquinoline-4-carboxylic acid-derivatives were selected and synthesized. Due to the presence of hydroxyl at position 3, all structures had a solubility of at least 0.5 mM. The affinities to ASGPR has been assessed using surface plasmon resonance (SPR) spectroscopy technique. All structures exhibited strong binding affinity with KD values in the nanomolar range (0.1 - 30 nM), that considerably exceed the affinities of native ASGPR ligands – N-acetylgalactosamine and galactose.
As all of the obtained compounds turned out to be potent ASGPR ligands one may consider quinoline-4-carboxylic acids to be a practically useful monovalent ligand as a cheaper, more available and more efficient GalNAc substituent as a vector for targeted drug delivery in hepatocytes.
FUNDING
This study was supported in part by the Russian Science Foundation grant 20-63-46029, State Topic АААА-А21-121011290089-4 and MSU Program of Development.
 
REFERENCES (4)
1.
Kaila N, Janz K, DeBernardo S, et al. Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists. J Med Chem. 2007;50(1):21-39. doi:10.1021/jm0602256
 
2.
Kaila N, Janz K, Huang A, et al. 2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic Acid (PSI-697):  Identification of a Clinical Candidate from the Quinoline Salicylic Acid Series of P-Selectin Antagonists. J Med Chem. 2007;50(1):40-64. doi:10.1021/jm060631p
 
3.
Huang A, Moretto A, Janz K, et al. Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury. J Med Chem. 2010;53(16):6003-6017. doi:10.1021/jm9013696
 
4.
Majouga AG, Ivanenkov YA, Veselov MS, et al. Identification of Novel Small-Molecule ASGP-R Ligands. Curr Drug Deliv. 2016;13(8):1303-1312. doi:10.2174/1567201813666160719144651
 
ISSN:2732-8929
Journals System - logo
Scroll to top